The Impact of MMF dosing on Donor specific Anti-HLA antibodies in the clinical management of kidney transplant recipient

The Impact of MMF dosing on Donor specific Anti-HLA antibodies in the clinical management of kidney transplant recipient - The Impact of MMF dosing on Donor specific Anti-HLA antibodies in the clinical management of kidney transplant recipient

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006576

Enrollment

300

Registered

2011-12-01

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney transplant recipients

Interventions

Control: Continue rencent immunosuppresive therapy Study: In case of under MMF daily dosage 1000mg,increasing 1500mg/day at first and final target dose at 2000mg/day In case of MMF daily dose from

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Subject inpatient or outpatient to participating hospitals 2. Subject recieved kidney transplantation within 1-5 years 3. Subject recieved MMF under 1500mg daily 4.Subject age under 20 y.o 5. Provision of written informed concent by subject

Exclusion criteria

Exclusion criteria: 1.Inablity or un willingness to provide written informed concent 2.Subject under 20 y.o 3.ABO blood type incombatibility kidney transplantation 4. Inable to outpatient treatment in study period 5.Pregnancy or possible to pregnant 6.Nursing 7.Serious digestive disease 8.hypoalbuminemia(2g/dl) 9.low WBC (3000/mm2) 10. Active infectious disease 11. Cancer 12.Recieved live vaccine within 3 month 13. Hypersensitity to MMF 14.Inablity or un willingness to comply with the requirements of the protocol by investigator

Design outcomes

Primary

Measure	Time frame
anti-HLA antibodies	—

Countries

Japan

Contacts

Public ContactMiyuki Furusawa, Hideki Ishida

Tokyo Women's Medical University Urology Unit

03-3358-0166

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026